2024 EBMT Meeting Reporter

Mohamad Mohty, MD, PhD, discusses unmet needs for patients with chronic or acute GVHD, for whom standard-of-care therapies often fall short.

Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EBMT Meeting, focusing on ongoing efforts within the GVHD treatment arena.

Amandeep Salhotra, MD, discusses the feasibility and safety of Orca-T graft in patients undergoing allogeneic transplant for hematologic malignancies.

Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.

Itacitinib prophylaxis showed signals for reducing CRS and ICANS following treatment with axicabtagene ciloleucel in patients with B-cell lymphoma.

Simulation-based education can improve health care professionals’ understanding and confidence regarding the treatment of patients with CAR T-cell therapy.

Orca-T demonstrated positive impacts on relapse-free survival and overall survival vs PTCy-based HSCT in acute leukemias and myelodysplastic syndrome.

The regulatory T cell enriched donor cell agent Orca-T was safe and displayed activity in the reduced intensity conditioning setting for patients with advanced hematologic malignancies.